Abstract: Myelin production by oligodendrocytes is essential for efficient neuronal communication, and disruptions in myelination are linked to various central nervous system disorders. Oligodendrocyte progenitor cells (OPCs) derived from human induced pluripotent stem cells (hiPSCs) offer a valuable platform for studying myelination in both 2D and 3D models. These systems enable controlled investigations of oligodendrocyte differentiation, myelination, and OPC-neuron interactions, supporting high-throughput drug screening for myelin repair and disease therapies.
To accelerate therapeutic discovery for demyelinating diseases, BrainXell developed an optimized protocol that reduces OPC differentiation time from three months to under one month, yielding highly pure OPC populations. Quantitative analysis showed significant MBP expression, with 60-80% of cells positive for MBP, and flow cytometry confirmed ~95% O4+ cells. qPCR demonstrated upregulation of oligodendrocyte-related genes (CNP, OLIG2, CSPG4) and myelin markers (PLP1, MBP).
In 2D co-culture with hiPSC-derived cortical glutamatergic neurons, MBP+ oligodendrocyte projections wrapped around MAP2+ neurites, indicating functional OPC-neuron interactions. In 3D nanofiber scaffolds, OPCs exhibited similar differentiation and maturation, demonstrating their myelination potential in a scaffold-based system. Both 2D and 3D cultures showed complex, arborized morphologies, confirming OPC maturation. Notably, in 3D cultures and co-cultures, OPCs displayed enhanced structural complexity with extended processes, resembling the in vivo environment more closely than monocultures. This underscores the value of 3D and co-culture systems for studying oligodendrocyte development and myelination, as they better mimic natural OPC-neuron interactions.
This optimized protocol facilitates the rapid generation of hiPSC-derived oligodendrocytes, accelerating myelin repair and regeneration therapeutic discovery. The platform supports functional OPC-neuron interactions in both 2D and 3D models, providing a robust system for drug screening and advancing therapies for myelin loss-related disorders.
